Compare Sirius XM Holdings Inc (SIRI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sirius XM Holdings Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Sirius XM Holdings Inc trades at $26.71 (market cap $8.87B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: Sirius XM Holdings Inc and State Street SPDR S&P Biotech ETF are close in size by market cap, and Sirius XM Holdings Inc pays a 4.1% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sirius XM Holdings Inc for 102 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SIRI | XBI | |
|---|---|---|
Market Cap | $8.87B | $10.11B |
Volume | 4,324,672 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $32.59 | $169.55 |
52-Week Low | $19.92 | $104.99 |
Typical Hold Time | 102 Days | 38 Days |
Enterprise Value | $18.16B | — |
Dividend Yield | 4.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sirius XM (SIRI) trades at $26.51, up 2.16% with mixed technical signals showing neutral momentum. The company demonstrates solid fundamentals with a P/E of 10.57 and P/B of 0.75, though recent earnings show volatility with two misses and one beat in the last four quarters. Strong cash flow generation and a new YouTube partnership provide growth catalysts, while high debt levels and competitive pressures remain concerns.
The stock presents a compelling value opportunity with analyst consensus pointing to 30% upside to the $34.43 price target. However, execution risks in advertising expansion and subscription growth, coupled with $10.31 billion in long-term debt, require careful monitoring. Recent institutional buying and positive management commentary suggest confidence in the company's strategic direction.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
